Virologic failure in first-line human immunodeficiency virus therapy with a CCR5 entry inhibitor, aplaviroc, plus a Fixed-dose combination of lamivudine-zidovudine: Nucleoside reverse transcriptase inhibitor resistance regardless of envelope tropism

Antimicrobial Agents and Chemotherapy

Volumn 53, Issue 3, 2009, Pages 1116-1123

  Demarest, James F ^a   Amrine Madsen, Heather ^a   Irlbeck, David M ^a   Kitrinos, Kathryn M ^a  

^a GLAXOSMITHKLINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3 TC AZT; APLAVIROC; CHEMOKINE RECEPTOR CCR5 ANTAGONIST; EFAVIRENZ; EI GW 873140; LAMIVUDINE PLUS ZIDOVUDINE; RNA DIRECTED DNA POLYMERASE INHIBITOR; UNCLASSIFIED DRUG;

ANTIBIOTIC RESISTANCE; ANTIVIRAL ACTIVITY; ARTICLE; CLINICAL PROTOCOL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; DRUG SENSITIVITY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; ENVELOPE GENE; GENE MUTATION; GENE SEQUENCE; GENOTYPE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; LIVER TOXICITY; MAJOR CLINICAL STUDY; NUCLEOTIDE SEQUENCE; PHENOTYPE; PHYLOGENY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; VIRUS DETECTION; VIRUS ENVELOPE;

ANTI-HIV AGENTS; BENZOATES; DRUG COMBINATIONS; DRUG RESISTANCE, VIRAL; ENV GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; HIV INFECTIONS; HIV-1; HUMANS; LAMIVUDINE; PHYLOGENY; PIPERAZINES; RECEPTORS, CCR5; REVERSE TRANSCRIPTASE INHIBITORS; SPIRO COMPOUNDS; TREATMENT FAILURE; TROPISM; ZIDOVUDINE;

EID: 62949107184     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01055-08     Document Type: Article

References (35)

1. Achaz, G., S. Palmer, M. Kearney, F. Maldarelli, J. W. Mellors, J. M. Coffin, and J. Wakeley. 2004. A robust measure of HIV-1 population turnover within chronically infected individuals. Mol. Biol. Evol. 21:1902-1912.
2. Berger, E. A., P. M. Murphy, and J. M. Farber. 1999. Chemokine receptors as HIV-1 coreceptors: roles in viral entry, tropism, and disease. Annu. Rev. Immunol. 17:657-700.
3. Brumme, Z. L., J. Goodrich, H. B. Mayer, C. J. Brumme, B. M. Henrick, B. Wynhoven, J. J. Asselin, P. K. Cheung, R. S. Hogg, J. S. Montaner, and P. R. Harrigan. 2005. Molecular and clinical epidemiology of CXCR4-using HIV-1 in a large population of antiretroviral-naive individuals. J. Infect. Dis. 192:466-474.
4. Coakley, E., J. Benhamida, C. Chappey, J. Whitcomb, J. Goodrich, E. van der Ryst, M. Westby, I. James, R. Tressler, P. R. Harrigan, and H. Mayer. 2006. An evaluation of tropism profiles and other characteristics among 3988 individuals screened for the A4001026, A4001027 (MOTIVATE 1), and A4001028 (MOTIVATE 2) studies for maraviroc, abstr. 8. Second Int. Workshop Target. HIV Entry, Boston, MA, 20 to 21 October 2006.
5. Colgrove, R., and A. Japour. 1999. A combinatorial ledge: reverse transcriptase fidelity, total body viral burden, and the implications of multiple-drug HIV therapy for the evolution of antiviral resistance. Antivir. Res. 41:45-56.
6. Currier, J., A. Lazzarin, L. Sloan, N. Clumeck, J. Slim, D. McCarty, H. Steel, J.-P. Kleim, T. Bonny, and J. Millard, on behalfofthe ASCENTStudyTeam. 2008. Antiviral activity and safety of aplaviroc with lamivudine/zidovudine in HIV-infected, therapy-naive patients: the ASCENT (CCR102881) study. Antivir. Ther. 13:297-306.
7. Demarest, J., T. Bonny, C. Vavro, C. LaBranche, K. Kitrinos, C. McDanal, S. Sparks, S. Chavers, S. Castillo, D. Elrick, D. McCarty, J. Whitcomb, W. Huang, C. Petropoulos, and S. Piscitelli. 2004. HIV envelope tropism in treatment naive and experienced subjects, abstr. H-1136. Abstr. 44th Inter-sci. Conf. Antimicrob. Agents Chemother. American Society for Microbiology, Washington, DC.
8. Demarest, J., T. Bonny, C. Vavro, C. LaBranche, K. Kitrinos, C. McDanal, S. Sparks, J. Whitcomb, W. Huang, C. Petropoulos, and S. Piscitelli. 2005. 873140 exhibits potent antiviral activity against a broad panel of HIV-1 envelopes from treatment naive and experienced subjects, abstr. TuPe6.1B13. Third IAS Conf. HIV Pathog. Treat., Rio de Janeiro, Brazil, 24 July 2005.
9. Demarest, J., S. Shibayama, R. Ferris, C. Vavro, M. St. Clair, and L. Boone. 2004. A novel CCR5 antagonist, 873140, exhibits potent in vitro anti-HIV activity, abstr. WeOr1231. XV Int. AIDS Conf., Bangkok, Thailand, 16 July 2004.
10. Gillespie, J. H. 2000. Genetic drift in an infinite population. The pseudohitchhiking model. Genetics 155:909-919.
11. Grant, R. M., F. M. Hecht, M. Warmerdam, L. Liu, T. Liegler, C. J. Petro-poulos, N. S. Hellmann, M. Chesney, M. P. Busch, and J. O. Kahn. 2002. Time trends in primary HIV-1 drug resistance among recently infected persons. JAMA 288:181-188.
12. Greaves, W., R. Landovitz, G. Fatkenhauer, C. Hoffman, F. Antunes, J. Angel, N. Boparai, D. Knepp, A. Keung, and L. Dunkle. 2006. Late virologic breakthrough in treatment naive patients on a regimen of combivir + vicri-viroc, abstr. 161LB. 13th Conf. Retrovir. Opportunistic Infect., Denver, CO, 5 February 2006.
13. Heera, J., M. Saag, P. Ive, J. Whitcomb, M. Lewis, L. McFadyen, J. Goodrich, H. Mayer, E. van der Ryst, and M. Westby. 2008. Virological correlates associated with treatment failure at week 48 in the phase 3 study of maraviroc in treatment-naive patients, abstr. 40LB. 15th Conf. Retrovir. Opportunistic Infect., Boston, MA, 3-6 February 2008.
14. Hudson, R. R. 2000. A new statistic for detecting genetic differentiation. Genetics 155:2011-2014.
15. Hudson, R. R., D. D. Boos, and N. L. Kaplan. 1992. A statistical test for detecting geographic subdivision. Mol. Biol. Evol. 9:138-151.
16. Johnson, V. A., F. Brun-Vezinet, B. Clotet, B. Conway, D. R. Kuritzkes, D. Pillay, J. M. Schapiro, A. Telenti, and D. D. Richman. 2005. Update of the drug resistance mutations in HIV-1: Fall 2005. Top. HIV Med. 13:125-131.
17. LaBranche, C., K. Kitrinos, R. Howell, C. McDanal, S. Harris, J. Jeffrey, and J. Demarest. 2005. Clonal analysis of in vitro-derived viruses with reduced susceptibility to aplaviroc (873140, APL) shows wide range in IC50 and sequence changes, abstr. 9. First Int. Workshop Target. HIV Entry, Bethesda, MD, 2 to 3 December 2005.
18. Lalezari, J., M. Thompson, P. Kumar, P. Piliero, R. Davey, K. Patterson, A. Shachoy-Clark, K. Adkison, J. Demarest, Y. Lou, M. Berrey, and S. Piscitelli. 2005. Antiviral activity and safety of 873140, a novel CCR5 antagonist, during short-term monotherapy in HIV-infected adults. AIDS 19:1443-1448.
19. Maeda, K., H. Nakata, Y. Koh, T. Miyakawa, H. Ogata, Y. Takaoka, S. Shibayama, K. Sagawa, D. Fukushima, J. Moravek, Y. Koyanagi, and H. Mitsuya. 2004. Spirodiketopiperazine-based CCR5 inhibitor which preserves CC-chemokine/CCR5 interactions and exerts potent activity against R5 human immunodeficiency virus type 1 in vitro. J. Virol. 78:8654-8662.
20. Melby, T., M. Despirito, R. DeMasi, G. Heilek-Snyder, M. L. Greenberg, and N. Graham. 2006. HIV-1 coreceptor use in triple-class treatment-experienced patients: baseline prevalence, correlates, and relationship to enfu-virtide response. J. Infect. Dis. 194:238-246.
21. Moyle, G. J., A. Wildfire, S. Mandalia, H. Mayer, J. Goodrich, J. Whitcomb, and B. G. Gazzard. 2005. Epidemiology and predictive factors for chemokine receptor use in HIV-1 infection. J. Infect. Dis. 191:866-872.
22. Nei, M. 1987. DNA polymorphism within and between populations, p. 254-286. In Molecular evolutionary genetics. Columbia University Press, New York, NY.
23. Nicholas, K. B., H. B. Nicholas, Jr., and D. W. Deerfield II. 1997. GeneDoc: analysis and visualization of genetic variation. EMBNEW News 4:14.
24. Nichols, W. G., H. M. Steel, T. Bonny, K. Adkison, L. Curtis, J. Millard, K. Kabeya, and N. Clumeck. 2008. Hepatotoxicity observed in clinical trials of aplaviroc (GW873140). Antimicrob. Agents Chemother. 52:858-865.
25. Petropoulos, C. J., N. T. Parkin, K. L. Limoli, Y. S. Lie, T. Wrin, W. Huang, H. Tian, D. Smith, G. A. Winslow, D. J. Capon, and J. M. Whitcomb. 2000. A novel phenotypic drug susceptibility assay for human immunodeficiency virus type 1. Antimicrob. Agents Chemother. 44:920-928.
26. Posada, D., and K. A. Crandall. 1998. MODELTEST: testing the model of DNA substitution. Bioinformatics 14:817-818.
27. Richman, D. D., S. C. Morton, T. Wrin, N. Hellmann, S. Berry, M. F. Shapiro, and S. A. Bozzette. 2004. The prevalence of antiretroviral drug resistance in the United States. AIDS 18:1393-1401.
28. Rozas, J., J. C. Sanchez-DelBarrio, X. Messeguer, and R. Rozas. 2003. DnaSP, DNA polymorphism analyses by the coalescent and other methods. Bioinformatics 19:2496-2497.
29. Swofford, D. L. 1998. PAUP*, phylogenetic analysis using parsimony (* and other methods) (4.0b10). Sinauer Associates, Sunderland, MA.
30. Thompson, J. D., T. J. Gibson, F. Plewniak, F. Jeanmougin, and D. G. Higgins. 1997. The CLUSTAL-X Windows interface: flexible strategies for multiple sequence alignment aided by quality analysis tools. Nucleic Acids Res. 25:4876-4882.
31. Trkola, A., S. E. Kuhmann, J. M. Strizki, E. Maxwell, T. Ketas, T. Morgan, P. Pugach, S. Xu, L. Wojcik, J. Tagat, A. Palani, S. Shapiro, J. W. Clader, S. McCombie, G. R. Reyes, B. M. Baroudy, and J. P. Moore. 2002. HIV-1 escape from a small molecule, CCR5-specific entry inhibitor does not involve CXCR4 use. Proc. Natl. Acad. Sci. USA 99:395-400.
32. Westby, M., C. Smith-Burchnell, J. Mori, M. Lewis, M. Mosley, M. Stockdale, P. Dorr, G. Ciaramella, and M. Perros. 2007. Reduced maximal inhibition in phenotypic susceptibility assays indicates that viral strains resistant to the CCR5 antagonist maraviroc utilize inhibitor-bound receptor for entry. J. Virol. 81:2359-2371.
33. Whitcomb, J., W. Huang, S. Fransen, T. Wrin, E. Paxinos, J. Toma, M. Greenberg, P. Sista, T. Melby, T. Matthews, R. DeMasi, G. Heilek-Snyder, N. Cammack, and N. Hellmann. 2007. Analysis of baseline enfuvirtide (T-20) susceptibility and coreceptor tropism in two phase III study populations, abstr. 557. 10th Conf. Retrovir. Opportunistic Infect., Boston, MA.
34. Whitcomb, J. M., W. Huang, S. Fransen, K. Limoli, J. Toma, T. Wrin, C. Chappey, L. D. B. Kiss, E. E. Paxinos, and C. J. Petropoulos. 2007. Development and characterization of a novel single-cycle recombinant-virus assay to determine human immunodeficiency virus type 1 coreceptor tropism. Antimicrob. Agents Chemother. 51:566-575.
35. Wilkin, T. J., Z. Su, D. R. Kuritzkes, M. Hughes, C. Flexner, R. Gross, E. Coakley, W. Greaves, C. Godfrey, P. R. Skolnik, J. Timpone, B. Rodriguez, and R. M. Gulick. 2007. HIV type 1 chemokine coreceptor use among antiretroviral-experienced patients screened for a clinical trial of a CCR5 inhibitor: AIDS Clinical Trial Group A5211. Clin. Infect. Dis. 44:591-595.